drugset / Trial / NCT00301873
Zoledronate in Preventing Osteoporosis in Patients With Primary Malignant Glioma
Phase 2
Completed
60 enrolled
Duke University
National Institute of Neurological Disorders and Stroke (NINDS) · collabNovartis · collab
NaSingle-groupOpen-labelSupportive care
Summary
RATIONALE: Zoledronate may prevent bone loss in patients with primary malignant glioma. PURPOSE: This phase II trial is studying how well zoledronate works in preventing osteoporosis in patients with primary malignant glioma.
Timeline
- Start
- 2006-05
- Primary completion
- 2011-02
- Completion
- 2012-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zoledronic acid | Other / unclassified | 4 mg | Intravenous |